7.04
Shattuck Labs Inc stock is traded at $7.04, with a volume of 947.37K.
It is down -5.25% in the last 24 hours and up +9.32% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$7.43
Open:
$7.37
24h Volume:
947.37K
Relative Volume:
0.79
Market Cap:
$672.38M
Revenue:
$1,000.00K
Net Income/Loss:
$-48.81M
P/E Ratio:
-9.0991
EPS:
-0.7737
Net Cash Flow:
$-39.95M
1W Performance:
+3.23%
1M Performance:
+9.32%
6M Performance:
+75.12%
1Y Performance:
+731.95%
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
STTK
Shattuck Labs Inc
|
7.04 | 709.63M | 1,000.00K | -48.81M | -39.95M | -0.7737 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-26 | Resumed | Needham | Buy |
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Dec-01-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-08-25 | Initiated | Wedbush | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
STTK|Shattuck Labs Inc|Price:7.430| - TradingKey
Shattuck Labs Inc (STTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
STTK|Shattuck Labs Inc|Price:7.430|Chg%:+0.340 - TradingKey
Shattuck Labs Inc (STTK) Balance Sheet - TradingKey
Shattuck Labs Inc (STTK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
STTK Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentFull Year Guidance - dars.gov.et
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday - The Globe and Mail
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday - The Motley Fool
STTK Initiated Coverage by JP Morgan -- Rating Set at Overweight - GuruFocus
This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
JPMorgan Initiates Shattuck Labs at Overweight With $10 Price Target - marketscreener.com
JPMorgan reiterates Shattuck Labs stock rating on DR3 program By Investing.com - Investing.com Canada
JPMorgan reiterates Shattuck Labs stock rating on DR3 program - Investing.com
Shattuck Labs Inc (STTK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Redmile Group, LLC Increases Stake in Shattuck Labs Inc - GuruFocus
Shattuck Labs Inc. (STTK) Drops Sharply as Biotech Sector Faces HeadwindsIron Condor Alert - dars.gov.et
STTK Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Form 13D/A Shattuck Labs For: 20 July By Investing.com - Investing.com Nigeria
STTK stock trades steady as Shattuck Labs highlights cash position and clinical progress - Ad-hoc-news.de
Form 13D/A Shattuck Labs For: 17 July By Investing.com - Investing.com Nigeria
Redmile updates 9.9% Shattuck Labs (STTK) stake after July trades - Stock Titan
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline UpdateSlideshow (NASDAQ:STTK) 2026-07-08 - Seeking Alpha
Shattuck Labs CTO Abhinav Shukla sells $2,874 in company stock By Investing.com - Investing.com Nigeria
Shattuck Labs CTO Abhinav Shukla sells $2,874 in company stock - Investing.com
Form 4 Shattuck Labs Inc For: 7 July By Investing.com - Investing.com Nigeria
Shattuck Labs (STTK) CTO exercises options and makes small 10b5-1 sale - Stock Titan
Shattuck Labs outlines its oncology platform as investors assess long-term prospects - ad-hoc-news.de
STTKShattuck Labs Inc Options - Finviz
STTK Q1 2026 Earnings: Narrower-Than-Expected Net Loss Boosts Investor SentimentRevenue Warning Signal - dars.gov.et
Shattuck Labs focuses on immunotherapy pipeline as investors watch clinical milestones - Ad-hoc-news.de
Insider Sell: Arundathy Pandite Sells 30,000 Shares of Shattuck Labs Inc (STTK) - GuruFocus
Shattuck Labs cmo Pandite sells $210,300 in company stock - Investing.com UK
Abhinav Shukla, Shattuck Labs CTO, sells $166,131 in stock By Investing.com - Investing.com South Africa
Form 4 Shattuck Labs Inc For: 2 July By Investing.com - Investing.com Canada
Shattuck Labs cmo Pandite sells $210,300 in company stock By Investing.com - Investing.com Australia
Abhinav Shukla, Shattuck Labs CTO, sells $166,131 in stock - Investing.com
Shattuck Labs (NASDAQ: STTK) CTO option exercises and 23,465-share sale disclosed - Stock Titan
Shattuck Labs (STTK) CMO sells 30,000 shares under 10b5-1 plan - Stock Titan
Form 144 Shattuck Labs For: 2 July By Investing.com - Investing.com Nigeria
410-share sale reported by STTK insider (NASDAQ: STTK) via option exercise - Stock Titan
Form 144 Shattuck Labs For: 1 July By Investing.com - Investing.com South Africa
Abhinav A. Shukla (STTK) files to sell 100 common shares via Form 144 - Stock Titan
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):